1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Zhongzhi Pharmaceutical Holdings Limited

Zhongzhi Pharmaceutical Holdings Limited

HHKEX:3737
0.62
HKD
+0.01
(+0.82%)
742.50MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
0.99
0.99
0.92
1.18
1.37
1.61
1.94
2.09
2.16
2.42
2.62
- -
Basic EPS, GAAP
0.14
0.12
0.07
0.09
0.1
0.14
0.17
0.06
0.13
0.19
0.11
- -
Free Cash Flow per Basic Share
0.17
0.04
-0.08
- -
- -
0.11
-0.04
-0.01
0.23
-0.08
0.05
- -
Dividend per Share
0.16
0.04
0.04
0.02
0.07
0.07
0.08
- -
- -
0.14
0.03
- -
Book Value per Share
0.15
0.71
0.72
0.8
0.85
0.92
0.99
1.06
1.18
1.24
1.32
1.29
Tangible Book Value per Share
0.15
0.7
0.7
0.77
0.82
0.87
0.93
1
1.16
1.22
1.31
1.26
Basic Weighted Avg Shares
600
694
794
799
833
833
829
837
847
847
845
844
Sales/Revenue/Turnover
596
688
730
945
1,142
1,342
1,604
1,747
1,826
2,050
2,215
- -
Operating Margin (%)
19.31
17.47
8.18
9.16
8.17
10.77
9.94
5.85
7.07
9.7
7.04
- -
Depreciation Expense
12
16
22
23
26
64
100
85
96
102
111
- -
Net Income, GAAP
87
81
54
70
85
115
139
52
106
163
95
- -
Effective Tax Rate (%)
24.49
20.41
22.1
22.05
16.45
26.45
17.1
15.28
18.17
20.93
34.55
- -
Profit Margin (%)
14.56
11.71
7.37
7.42
7.45
8.55
8.64
2.98
5.83
7.94
4.3
- -
Working Capital
27
451
362
428
413
416
398
357
360
266
283
340
LT Debt
- -
- -
- -
- -
- -
64
73
81
95
99
107
96
Total Equity
121
563
568
668
707
763
822
901
1,006
1,053
1,122
1,091
Return on Invested Capital (%)
- -
26.25
7.91
9.88
10.05
12.68
13.32
7.95
8.53
11.87
6.8
- -
Return on Capital (%)
- -
23.22
9.42
11.04
12.23
14.73
15.02
5.55
9.7
13.43
7.32
- -
Return on Common Equity (%)
- -
23.56
9.53
11.33
12.37
15.6
17.5
6.07
11.19
15.87
8.8
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
ST Debt
196
194
185
LT Borrowings
38
38
38
LT Finance Leases
82
69
58
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
845
844
844
Market Capitalization
983
785
678

Working Capital

CNY

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
Total Current Assets
977
1,014
971
Cash, Cash Equivalents & STI
163
167
146
Accounts Receivable, Net
295
317
328
Inventories
344
345
302
Total Current Liabilities
700
732
631
Payables & Accruals
- -
- -
- -
ST Debt
196
194
185
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
43.79%
8.03%
6.48%
Free Cash Flow
-107.7%
-532.02%
-156.66%
Net Income, GAAP
12.01%
14.8%
-41.51%
Sales/Revenue/Turnover
14.27%
10.65%
8.05%
Total Cash Common Dividend
- -
- -
-80.08%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2,050
2024
- -
- -
2,215
2025
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.19
2024
- -
- -
0.11
2025
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.14
2024
- -
- -
0.03
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ying Feng Lai
Full Time Employees
2,284
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 3 Kangtai Road South Zhongshan GD China
IPO Date
Jul 13, 2015
Website
zeus.cn
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Zhongzhi Pharmaceutical Holdings Limited is an investment holding company engaged in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through two main segments, Pharmaceutical Manufacturing and Operation of Chain Pharmacies; it produces and sells Chinese patent medicines and decoction pieces under the Zeus (中智), Liumian (六脉), and Caojinghua (草晶华) brand names, including traditional and modern decoction pieces, broken-wall herbal products, healthcare foods, and Chinese herbs, while also providing detection and testing services, property management, pharmaceutical wholesaling, and traditional Chinese medicine services through its chain pharmacies under the Zeus brand. Zhongzhi Pharmaceutical Holdings Limited maintains 45 herbal ecological traceability planting bases, manufactures food and medical devices sourced from suppliers, and targets domestic markets via its subsidiaries such as Zhongshan Hengsheng Pharmaceutical, Guangdong Yunzhi Chinese Medicine Pieces, and Guangdong Caijinghua Broken-Wall Herbal; founded in 1993, the company is headquartered at No. 3 Kangtai Road South, Torch Development Zone, Zhongshan, Guangdong, and lists as a subsidiary of Crystal Talent Investment Group Limited on the Hong Kong Stock Exchange (3737.HK). In 2024, the company continues to expand its traditional Chinese medicine decoction pieces business under the core Caojinghua brand; insiders, including Chairman Lai Zhi Tian, conducted share acquisitions in April 2024 at prices around HK$0.15-0.16 per share to bolster ownership.